Clinical Trial

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

Study acronym: PROSPECTOR
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-01
Trial Details
NCT Number NCT07590934
Lead Sponsor AstraZeneca
Conditions Metastatic Prostate Cancer
Enrollment 152 participants
Start Date 2026-06-03
Primary Completion 2029-09-25 (estimated)
Study Completion 2029-09-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-30